Our results, in agreement with previous observations indicating altered levels of cholinesterases in serum, plasma and CSF of MS patients [18], may explain why the use of cholinesterase inhibitors could decrease the release of pro-inflammatory cytokines, reduce neuro-inflammation, ameliorate EAE symptoms and improve cognitive deficit [37,38]. The gene discussed is BCHE; the disease is myeloid sarcoma.